Published in Drug Law Weekly, June 5th, 2007
"Protox made substantial progress during the first quarter and has set the stage for continued clinical advances in 2007 and beyond," said Dr. Fahar Merchant, President and CEO of Protox. "The first quarter marked two significant milestones for our flagship drug candidate PRX302. While early, the encouraging interim clinical trial results released in January support the potential for this drug as a groundbreaking treatment for prostate cancer. In addition, the initiation of our Phase I clinical trial for the treatment of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.